CONTACT US   |  (864) 397-5101

Zylö Therapeutics locating new operations in Greenville County, South Carolina

GREENVILLE, S.C. – Zylö Therapeutics, a developer of state-of-the-art technology for the pharmaceutical industry, is locating new operations in Greenville County. The company is expected to create 30 new jobs.

Zylö Therapeutics has developed an innovative sustained-release drug-delivery system that delivers traditionally hard-to-deliver therapeutic agents through topical administration. With more than 10 years of research and development, the second generation of this technology continues to improve, providing 24-hour sustained release of a variety of agents, including nitric oxide, curcumin, lidocaine and more.

Zylö Therapeutics is headquartered at the NEXT on Main facility at 101 North Main Street in Greenville, S.C. NEXT is a program of the Greenville Chamber of Commerce that currently supports more than 100 knowledge-based companies in Upstate South Carolina.

Zylö Therapeutics’ operations will soon include a lab facility, where formulation and product development work will be performed. Those interested in joining the Zylö Therapeutics team should visit for more information.


“With the bulk of our scientists and advisors located in the Northeast corridor, we considered a variety of alternative locations, but Greenville represents a wonderful balance of small-town feel, sophistication, high growth and vibrancy. In addition, the city offers a wealth of start-up resources that will assuredly work to our advantage over time.” – Zylö Therapeutics CEO Scott Pancoast

“To see a company like Zylö Therapeutics choose to invest in our state and our people is an important sign to the business community around the world that South Carolina is the place to be. We’ve worked hard to create a pro-business environment and cultivate a highly-trained workforce, and those efforts continue to pay off.” –Gov. Henry McMaster

“The success of South Carolina’s booming life sciences industry continues to impress, and I congratulate Zylö Therapeutics on today’s tremendous announcement. Over the last two decades, we’ve seen a major transformation in South Carolina’s economy, and innovative companies like Zylö Therapeutics are responsible for it.” –Secretary of Commerce Bobby Hitt

“Greenville County encourages growth in the bioscience sector of our economy. We are proud to welcome Zylö Therapeutics to Greenville as part of our vibrant bioscience community that is pioneering state-of-the-art technologies at the forefront of modern medicine. We wish great success for Zylö Therapeutics.” –Greenville County Council Chairman H.G. “Butch” Kirven Jr.

“Greenville has become increasingly attractive to industry leaders in next-generation medical care, as innovative companies like Zylö Therapeutics seek environments that can help connect resources, support emerging technologies and supply a dedicated workforce. The City of Greenville is thrilled to welcome Zylö to our vibrant downtown and we look forward to being a part of their company’s growth.” –City of Greenville Mayor Knox White

“We are excited to welcome Zylö Therapeutics as the newest member of NEXT and the Greenville startup community. This high-impact, knowledge-based company further strengthens the more-than-150 companies within this vibrant, entrepreneurial ecosystem.” –NEXT CEO John Moore


  • Zylö Therapeutics is locating new operations in Greenville County.
  • The start-up is projected to create 30 new jobs.
  • Zylö Therapeutics is a developer of patented, state-of-the-art technology for the pharmaceutical industry.
  • Headquartered in Suite 315 at 101 North Main Street in Greenville, S.C., the company’s operations will include a laboratory facility focused on formulation and product development.
  • Those interested in joining the Zylö Therapeutics team should visit for more information. 

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.